Updated information and services can be found at: We investigated the ability of interleukin 10 (IL-10) to protect mice against lethal shock induced by staphylococcal enterotoxin B (SEB). Treatment of mice with IL-10 prevented the death of mice injected with SEB in a dose-dependent manner. IL-10-mediated protection was apparent when administered either prior to or concurrent with SEB but was less effective when administered following SEB injection. This observation
indicates that IL-10 is capable of regulating T-celi activation in vivo.
Superantigens are mitogens that activate T cells in a V,B-specific manner (11) . They include endogenous molecules produced by murine mammary tumor viruses (reviewed in reference 17) and exogenous superantigens, such as enterotoxins produced by Staphylococcus aureus (20) . The mitogenic effect of superantigens depends on the presence of antigen-presenting cells (APC) since they act by binding the a chain of major histocompatibility complex class II molecules with the a chain of the T-cell receptor. Recently it has been recognized that the toxic effect of these enterotoxins is due to their T-cell mitogenic activity (13) , a phenomenon that has been demonstrated in vivo (15) .
Interleukin 10 (IL-10) is a cytokine which exhibits pleiotropic activities on a variety of cell lineages, including a growth cofactor for murine T cells and mast cells, Ia induction in B cells, and ability to inhibit T-cell activation (reviewed in reference 21). The last activity has been demonstrated to be indirect, by inhibiting the ability of macrophages to act as APC (7) . This effect seems to be part of a general inhibitory influence of IL-10 on macrophage function, which includes the ability to inhibit the production of cytokines such as IL-1, tumor necrosis factor alpha (TNFa), and IL-6 (6). The significance of these results has been demonstrated in recent experiments in which IL-10 has been shown to protect mice from lipopolysaccharide (LPS)-induced lethal shock, presumably through its ability to prevent TNF-a production (as well as that of other cytokines) by LPS-activated macrophage/monocytes (9, 10) . It is therefore possible that IL-10 may have a therapeutic role in the treatment of septic shock.
In the present study, we used an in vivo model of T-cell-mediated lethal shock induced in mice by staphylococcal enterotoxin B (SEB) (15) . In this model, mice are rendered sensitive to the toxic effects of SEB by pretreatment with D-galactosamine (8) . This treatment lowers the natural resistance that mice exhibit towards enterotoxins, possibly by altering liver clearance mechanisms (8) . Subsequent administration of small doses of SEB induces death within a few hours due to extensive in vivo T-cell activation and subsequent TNF-a production (15) . This model exhibits a fundamental difference from LPS-induced lethal shock, in which toxicity is probably mediated by increased production of TNF-a and other inflammatory mediators by activated * Corresponding author. macrophages; in SEB-induced lethal shock, the main source of TNF-a is T cells. Possibly the best demonstration of this hypothesis is that SCID mice are susceptible to LPS but not to SEB-mediated lethal shock (15) . Here, we report that treatment of mice with IL-10 inhibits SEB-mediated lethal shock, presumably through its ability to inhibit macrophagedependent T-cell activation.
Groups of at least five BALB/c mice, 6-to 8-week-old males each weighing approximately 20 g (Simonsen Laboratories, Gilroy, Calif.), were injected intraperitoneally with D-galactosamine (30 mg per mouse; Sigma, St. Louis, Mo.) followed by SEB (25 ,ug per mouse; Toxin Technology, Sarasota, Fla.) 1 h later. Test mice were injected with purified recombinant mouse IL-10 (prepared as described previously [10] ), at various times (from 3 h before to 3 h after SEB administration) and concentrations (10 to 0.1 ,ug per mouse). Samples were resuspended in balanced salt solution and filter sterilized for injection. Control mice were injected with either balanced salt solution alone or inactivated IL-10 (heat denatured by 10 min of boiling). During treatment, mice were inspected at 12, 18, 24, 36, and 48 h postinjection. Data were analyzed and statistical significance was calculated by using Student's unpaired t test.
Initially, we sought to establish whether IL-10 altered the toxicity of SEB in vivo. Preliminary experiments indicated that the minimum dose of SEB required to observe high mortality in this model was 25 ,g per mouse. To investigate the effects of IL-10 in this system, mice were injected with 10 ,ug of IL-10 at the same time as SEB challenge. The IL-10-treated mice displayed a significantly higher survival rate than those treated with SEB alone (Fig. 1) . Injection of IL-10 (10 pg per mouse) or D-galactosamine (30 mg per mouse) alone had no apparent toxic effects. In these experiments, the viability of test animals did not vary after 48 h.
We then investigated the times at which IL-10 needed to be administered to observe this protective effect. IL-10 was injected before, simultaneously with, and after SEB challenge. Significant protection was observed when IL-10 was given prior to or simultaneously with SEB (Fig. 2) . After this time, the ability of IL-10 to protect diminished quickly and by 1 h after SEB injection IL-10-mediated protection was minimal. This observation, in conjunction with the rapid onset of death (at an average of 12 h), suggests rapid kinetics of cytokine production in vivo, a conclusion supported by a recent study of Litton et al. (12a) , who analyzed cytokine production by T cells in vivo following injection of SEB. protects mice from SEB-mediated toxic shock in a dosedependent manner. Significant IL-10-mediated protection was observed at a dose of 10 ,ug per mouse; 1 ,ug per mouse rapILd onset of death in this model, it is not induced partial protection while 0.1 ,g per mouse did not iat IL-1 administration was required soon after induce significant protection (Fig. 3) . superantigen-mediated toxicity in vivo. Given that superand concurrently with SEB, showed that IL-10 tigens are molecules that activate T cells by binding the VP chain of the T-cell receptor (3) and major histocompatibility complex class II molecules present on APC (5) and that IL-10 inhibits cytokine production by T cells (7) through its inhibitory effect on macrophage APC function (6), we rea-** ** *** *** soned that IL-10 may inhibit cytokine production by T cells (1, 12) , and other disorders caused by these toxins (2, 19) . Superantigens have also been implicated in some autoimmune diseases, such as rheumatoid arthritis (16) ; there exists the possibility that IL-10 may have some recuperative role in these diseases. Furthermore, IL-10 may have other therapeutic influences through its ability to inhibit T-cell activation in vivo mediated by regular antigens rather than superantigens. Future experiments will aim to investigate these possibilities.
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